EMAIL THIS PAGE TO A FRIEND

EMBO reports

Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.


PMID 27993939

Abstract

Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC